Trial Profile
A Phase Ia, Open Label, Single Ascending Dose Study to Assess the Safety and Tolerability of KSI 301 in Patients with Diabetic Macular Oedema
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Aug 2019
Price :
$35
*
At a glance
- Drugs Tarcocimab tedromer (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions; First in man
- Sponsors Kodiak Sciences
- 14 Aug 2019 According to a Kodiak Sciences media release, data presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting highlighted the final 12-week results of the Phase 1a clinical study of KSI-301 with sustained responses observed after a single dose of KSI-301, measured as improvement from baseline in vision, retinal anatomy, or both.
- 25 Apr 2019 According to a Kodiak Sciences media release, the data from this study will be made at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting.
- 28 Mar 2019 According to a Kodiak Sciences media release, the data from this study were presented at the Angiogenesis, Exudation, and Degeneration 2019 medical meeting on February 9, 2019.